Serum Institute could resume Covishield shot production as Covid cases spike
☰
India

Serum Institute could resume Covishield shot production as Covid cases spike

NEW DELHI (Reuters) - The Serum Institute of India (SII) could resume production of the Covishield COVID-19 vaccine, a company spokesperson said on Wednesday, as infections rise in the country. The

Sakshi Dayal    
Vials of AstraZeneca's Covidshield are seen inside a visual inspection machine inside a lab at the Serum Institute of India in Pune | Reuters file photo

Vials of AstraZeneca's Covidshield are seen inside a visual inspection machine inside a lab at the Serum Institute of India in Pune | Reuters file photo

New Delhi: The Serum Institute of India (SII) could resume production of the Covishield COVID-19 vaccine, a company spokesperson said on Wednesday, as infections rise in the country.

The world’s biggest vaccine maker already has a stock of 6 million doses of Covovax, a version of a Novavax vaccine, the spokesperson added. Covishield is a version of an AstraZeneca shot.

(Reporting by Sakshi Dayal; Editing by Krishna N. Das)

Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.

Also read: In leg-up to vaccination, SII’s Covovax on CoWin as heterologous booster, to cost Rs 225